{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:21:14Z","timestamp":1790749274984,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Spanish Ministry of Economy and Competitiveness","award":["SAF2011-22506"],"award-info":[{"award-number":["SAF2011-22506"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The International Journal of Biochemistry & Cell Biology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.biocel.2015.04.009","type":"journal-article","created":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T18:31:06Z","timestamp":1430591466000},"page":"45-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Epigenetic-based therapies in the preclinical and clinical treatment of Huntington's disease"],"prefix":"10.1016","volume":"67","author":[{"given":"Luis M.","family":"Valor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biocel.2015.04.009_bib0005","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/hmg\/ddu561","article-title":"Epigenetic dysregulation of hairy and enhancer of split 4 (HES4) is associated with striatal degeneration in postmortem Huntington brains","volume":"24","author":"Bai","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.biocel.2015.04.009_bib0010","series-title":"Huntington's disease","year":"2004"},{"key":"10.1016\/j.biocel.2015.04.009_bib0015","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1039\/b703830p","article-title":"Isoform-selective histone deacetylase inhibitors","volume":"37","author":"Bieliauskas","year":"2008","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.biocel.2015.04.009_bib0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00441-014-1862-4","article-title":"Histone variants: key players of chromatin","volume":"356","author":"Biterge","year":"2014","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.biocel.2015.04.009_bib0025","doi-asserted-by":"crossref","first-page":"256ra135","DOI":"10.1126\/scitranslmed.3009278","article-title":"Histone deacetylase inhibition rescues structural and functional brain deficits in a mouse model of Kabuki syndrome","volume":"6","author":"Bjornsson","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.biocel.2015.04.009_bib0030","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/hmg\/8.9.1647","article-title":"Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin","volume":"8","author":"Boutell","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.biocel.2015.04.009_bib0035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jgg.2013.05.001","article-title":"Histone variants in development and diseases","volume":"40","author":"Chen","year":"2013","journal-title":"J Genet Genom"},{"key":"10.1016\/j.biocel.2015.04.009_bib0040","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.biocel.2015.04.009_bib0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17482960802320487","article-title":"Phase 2 study of sodium phenylbutyrate in ALS","volume":"10","author":"Cudkowicz","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1016\/j.biocel.2015.04.009_bib0050","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.biocel.2015.04.009_bib0055","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.tips.2010.09.003","article-title":"Targeting the correct HDAC(s) to treat cognitive disorders","volume":"31","author":"Fischer","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.biocel.2015.04.009_bib0060","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group","volume":"72","author":"The Huntington's Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.biocel.2015.04.009_bib0065","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/mds.21632","article-title":"Sodium phenylbutyrate in Huntington's disease: a dose-finding study","volume":"22","author":"Hogarth","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.biocel.2015.04.009_bib0070","doi-asserted-by":"crossref","first-page":"17141","DOI":"10.1073\/pnas.1104409108","article-title":"Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse","volume":"108","author":"Hu","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biocel.2015.04.009_bib0075","doi-asserted-by":"crossref","first-page":"E56","DOI":"10.1073\/pnas.1415195112","article-title":"HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation","volume":"112","author":"Jia","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biocel.2015.04.009_bib0080","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nm.2558","article-title":"Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets","volume":"18","author":"Jiang","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.biocel.2015.04.009_bib0085","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1073\/pnas.96.20.11404","article-title":"Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells","volume":"96","author":"Kazantsev","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biocel.2015.04.009_bib0090","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.biocel.2015.04.009_bib0095","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/sj.cdd.4402219","article-title":"Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation","volume":"14","author":"Li","year":"2007","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.biocel.2015.04.009_bib0100","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.tig.2014.09.003","article-title":"Can changes in histone acetylation contribute to memory formation?","volume":"30","author":"Lopez-Atalaya","year":"2014","journal-title":"Trends Genet"},{"key":"10.1016\/j.biocel.2015.04.009_bib0105","doi-asserted-by":"crossref","DOI":"10.1038\/ejhg.2014.281","article-title":"Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood","author":"Mastrokolias","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.biocel.2015.04.009_bib0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/01.wnl.0000249142.82285.d6","article-title":"Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy","volume":"68","author":"Mercuri","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.biocel.2015.04.009_bib0115","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1126\/science.1056784","article-title":"Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity","volume":"291","author":"Nucifora","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.biocel.2015.04.009_bib0120","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1254\/jphs.13R02CP","article-title":"Mithramycin, an agent for developing new therapeutic drugs for neurodegenerative diseases","volume":"122","author":"Osada","year":"2013","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.biocel.2015.04.009_bib0125","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1093\/hmg\/ddn273","article-title":"Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease","volume":"17","author":"Pallos","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.biocel.2015.04.009_bib0130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0197-4580(03)00087-3","article-title":"Effects of beta-hydroxybutyrate on cognition in memory-impaired adults","volume":"25","author":"Reger","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.biocel.2015.04.009_bib0135","doi-asserted-by":"crossref","first-page":"19176","DOI":"10.1073\/pnas.0606373103","article-title":"ESET\/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease","volume":"103","author":"Ryu","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biocel.2015.04.009_bib0140","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.1227166","article-title":"Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor","volume":"339","author":"Shimazu","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.biocel.2015.04.009_bib0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1750-1326-8-7","article-title":"HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?","volume":"8","author":"Simoes-Pires","year":"2013","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.biocel.2015.04.009_bib0150","doi-asserted-by":"crossref","first-page":"14328","DOI":"10.1523\/JNEUROSCI.1010-14.2014","article-title":"Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition","volume":"34","author":"Sleiman","year":"2014","journal-title":"J Neurosci"},{"key":"10.1016\/j.biocel.2015.04.009_bib0155","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1093\/hmg\/ddu010","article-title":"A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease","volume":"23","author":"Smith","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.biocel.2015.04.009_bib0160","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/hmg\/ddm064","article-title":"Modulation of nucleosome dynamics in Huntington's disease","volume":"16","author":"Stack","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.biocel.2015.04.009_bib0165","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription","volume":"97","author":"Steffan","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biocel.2015.04.009_bib0170","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0378-1119(99)00357-1","article-title":"The Sp-family of transcription factors","volume":"238","author":"Suske","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.biocel.2015.04.009_bib0175","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bcp.12512","article-title":"An exploratory double blind, randomised clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease","volume":"79","author":"Sussmuth","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.biocel.2015.04.009_bib0180","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1073\/pnas.0804249105","article-title":"The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice","volume":"105","author":"Thomas","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biocel.2015.04.009_bib0185","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12035-014-8715-8","article-title":"Transcription, epigenetics and ameliorative strategies in Huntington's disease: a genome-wide perspective","volume":"51","author":"Valor","year":"2015","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.biocel.2015.04.009_bib0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neuropharm.2013.10.025","article-title":"What's wrong with epigenetics in Huntington's disease?","volume":"80","author":"Valor","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biocel.2015.04.009_bib0195","doi-asserted-by":"crossref","first-page":"E3027","DOI":"10.1073\/pnas.1311323110","article-title":"Targeting H3K4 trimethylation in Huntington disease","volume":"110","author":"Vashishtha","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biocel.2015.04.009_bib0200","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12017-013-8219-0","article-title":"Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease","volume":"15","author":"Villar-Menendez","year":"2013","journal-title":"Neuromol Med"},{"key":"10.1016\/j.biocel.2015.04.009_bib0205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.brainres.2013.02.012","article-title":"Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington's disease","volume":"1504","author":"Yeh","year":"2013","journal-title":"Brain Res"},{"key":"10.1016\/j.biocel.2015.04.009_bib0210","doi-asserted-by":"crossref","first-page":"42428","DOI":"10.1074\/jbc.R112.372300","article-title":"Structural basis for sirtuin activity and inhibition","volume":"287","author":"Yuan","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biocel.2015.04.009_bib0215","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pbb.2009.08.001","article-title":"Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease","volume":"94","author":"Zadori","year":"2009","journal-title":"Pharmacol Biochem Behav"}],"container-title":["The International Journal of Biochemistry & Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272515001107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1357272515001107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:03:08Z","timestamp":1761202988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1357272515001107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":43,"alternative-id":["S1357272515001107"],"URL":"https:\/\/doi.org\/10.1016\/j.biocel.2015.04.009","relation":{},"ISSN":["1357-2725"],"issn-type":[{"value":"1357-2725","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic-based therapies in the preclinical and clinical treatment of Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"The International Journal of Biochemistry & Cell Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biocel.2015.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}